Andrew Kuykendall

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

Andrew Kuykendall, Savan Shah, Chetasi Talati et al. · Annals of Hematology · 2017 · 126 citations

Translational Medicine, Ruxolitinib Discontinuation, Hard Place +5

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Aaron T. Gerds, Jason Gotlib, Haris Ali et al. · Journal of the National Comprehensive Cancer Network · 2022 · 119 citations · Full text

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Margherita Maffioli, Barbara Mora, Somedeb Ball et al. · Blood Advances · 2022 · 108 citations · Full text

Survival following allogeneic transplant in patients with myelofibrosis

Krisstina Gowin, Karen K. Ballen, Kwang Woo Ahn et al. · Blood Advances · 2020 · 94 citations · Full text